Home / Psoriasis (page 22)


Here you will find the latest clinical research on psoriasis.

OWCP and mediq Collaborate to Introduce Cannabinoid-based Psoriasis Cream in Germany

One World Cannabis Pharmaceutical Research (OWCP) and mediq Innovation Experts have partnered to introduce OWCP’s cannabinoid-based topical psoriasis cream in Germany. Germany-based mediq has extensive experience in assisting companies based in Israel enter European markets. Under the new agreement, mediq will support OWCP with both a scientific collaboration and in marketing …

Read More »

Experts endorse routine screening for pediatric psoriasis comorbidities

pediatric psoriasis comorbidities

Pediatric psoriasis patients should be screened regularly to identify risk factors for comorbidities including depression, gastrointestinal problems, diabetes, and dyslipidemia, according to the debut guidelines issued by an expert panel. The National Psoriasis Foundation and the Pediatric Dermatology Research Alliance joined forces to assess the literature and develop recommendations for …

Read More »

Pediatric psoriasis may have a distinct presentation

Pediatric psoriasis

Children may have a distinctive presentation of psoriasis, compared with adults, Dr. Wynnis Tom said at a pediatric dermatology meeting sponsored by Rady Children’s Hospital–San Diego and UC San Diego School of Medicine. Infants may present with diaper involvement, also known as “napkin psoriasis,” which may be confused with irritant …

Read More »

Healthcare Expenditures of Psoriasis Examined

Psoriasis healthcare costs

In 2012, the top 10% (T10) of psoriasis patients accounted for nearly 40% of overall healthcare expenditures among enrollees with psoriasis in a US health plan, a recent study found. Researchers conducted a retrospective study of patients with psoriasis with continuous enrollment in a plan from January 1, 2011, to …

Read More »

Risankizumab tops ustekinumab in phase II psoriasis trial

Psoriasis treatment

Key clinical point: Clinical responses in psoriasis patients treated with risankizumab were superior to responses in patients treated with ustekinumab. Major finding: At 12 weeks, 77% of risankizumab patients showed a 90% or greater reduction in PASI score, compared with 40% of ustekinumab patients. Data source: A phase II randomized …

Read More »